Packaging Goes Green - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Packaging Goes Green
Pharmaceutical companies get ideas for sustainable packaging from other industries.


Pharmaceutical Technology
Volume 33, Issue 10

Degradable PET controversy

Another material receiving lots of attention, degradable PET, sounds like an ideal choice for green packaging because so much PET packaging ends up as litter, ocean pollution, or in landfills. Three trade associations have reservations about this PET, which includes additives to make it degradable. The associations fear that the material could cause problems for PET recycling and recycled-content PET products.

NAPCOR contends that suppliers of degradable PET need to substantiate claims of degradability, investigate the effect of degradable additives on the quality of the PET recycling stream, examine the effects of degradable additives on products made of RPET, and learn how the material changes the service life of these products.

"We don't yet understand the impacts that these additives could have on the quality of the PET recycling stream, let alone the impacts on the safety and functionality over time of next-use PET products like recycled-content PET packaging, carpeting, or strapping," explains Sabourin.

EurPR (Brussels), a trade association for plastics recyclers, echoes NAPCOR's concerns and is particularly worried about whether oxo-biodegradable PET will pose problems in recycling operations.

European Bioplastics (Berlin) also has issued warnings about oxo-biodegradable plastic containers, claiming that no evidence shows that these materials meet international standards regarding biodegradation and compostability such as the International Organization for Standardization's ISO 17088 Specifications for Compostable Plastics or European Norm 13432 Requirements for Packaging Recoverable through Composting and Biodegradation. "If certain products that claim to be biodegradable or compostable are proven not to fulfill acknowledged standards, this is liable to impact negatively on our own members' products, even though they do fully comply," explains Andy Sweet-man, chairman of the board of European Bioplastics.

But a maker of oxo-biodegradable additives argues that its material complies with the degradability, biodegradability, and nonecotoxicity requirements of the American Soceity for Testing and Materials's D6954-04 Standard Guide for Exposing and Testing Plastics that Degrade in the Environment by a Combination of Oxidation and Biodegradation (Symphony Environmental Technologies, London).

Another maker of a degradable additive also claims compliance with ASTM standards for biodegradability and recyclability and has confirmed results with third-party testing and validation. This additive is not classified as oxo-biodegradable, but enables the PET to degrade in anaerobic and aerobic environments by attracting microbes that convert the resin into humus and gases such as carbon dioxide and methane. Because it does not chemically bond to the PET, it reportedly has no effect on bottle weight or properties. Testing also has shown that the material has no negative effect on the PET recycling stream (EcoPure degradable additive for PET, ENSO Bottles, Phoenix, AZ).

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here